Conjugate vaccines (e.g., Hib, pneumococcal PCV13, meningococcal MCV4) are superior to polysaccharide vaccines in infants under 2 years because:
- A Polysaccharides are T-independent antigens that cannot activate immature infant B-cells; conjugation to a carrier protein converts the response to T-dependent, inducing memory ✓
- B Conjugate vaccines elicit IgA secretory antibody which polysaccharide vaccines cannot
- C Conjugate vaccines contain adjuvants (e.g., AS04) that boost innate immunity in infants
- D Polysaccharide vaccines are inactivated whole organisms that can revert to virulence in infants
Explanation
Plain polysaccharide antigens (T-independent type 2 antigens) stimulate marginal zone B-cells directly without T-cell help, producing only short-lived IgM with no immunological memory and no booster effect — this response is absent or minimal in children under 2 years whose marginal zone is immature. Conjugating polysaccharide to a carrier protein (diphtheria CRM197, tetanus toxoid, or meningococcal OMPC) converts the response to T-cell-dependent, enabling class switching (IgG), affinity maturation, and memory B-cell formation, providing long-lasting protection in all age groups.
Reference: Ananthanarayan & Paniker's Textbook of Microbiology, 11th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.